Illumina (Illumina) Net Margin %

: -15.60% (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Net margin is calculated as Net Income divided by its Revenue. Illumina's Net Income for the three months ended in Dec. 2023 was $-175 Mil. Illumina's Revenue for the three months ended in Dec. 2023 was $1,122 Mil. Therefore, Illumina's net margin for the quarter that ended in Dec. 2023 was -15.60%.

The historical rank and industry rank for Illumina's Net Margin % or its related term are showing as below:

ILMN' s Net Margin % Range Over the Past 10 Years
Min: -96.07 Med: 19.78 Max: 28.28
Current: -25.76

ILMN's Net Margin % is ranked worse than
57.08% of 226 companies
in the Medical Diagnostics & Research industry
Industry Median: -11.145 vs ILMN: -25.76

Illumina Net Margin % Historical Data

The historical data trend for Illumina's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

28.28

20.25

16.84

-96.07

-25.78

Illumina Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %																-12.83	0.28	-19.90	-67.38	-15.60

Competitive Comparison

For the Diagnostics & Research subindustry, Illumina's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Illumina Net Margin % Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Net Margin % distribution charts can be found below:

* The bar in red indicates where Illumina's Net Margin % falls into.

Illumina Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Illumina's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-1161	/	4504
	=	-25.78 %

Illumina's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-175	/	1122
	=	-15.60 %

Illumina (NAS:ILMN) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Illumina Net Margin % Related Terms

Thank you for viewing the detailed overview of Illumina's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Illumina (Illumina) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (NAS:ILMN) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

ILMN:Mexico 1ILMN:Italy ILU:Germany ILU:Germany ILU:Germany ILMN:Austria

Address

5200 Illumina Way, San Diego, CA, USA, 92122

Website

https://www.illumina.com

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Executives

Aimee L Hoyt	officer: SVP, Chief People Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jacob Thaysen	director, officer: Chief Executive Officer	5301 STEVENS CREEK BLVD., SANTA CLARA CA 95051
Susan H Tousi	officer: SVP Product Development	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Steven Barnard	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott B. Ullem	director	C/O EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE CA 92614
Stephen P Macmillan	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Andrew Teno	director	C/O FIR TREE INC., 55 WEST 46TH STREET, 29TH FLOOR, NEW YORK NY 10036
Alexander Aravanis	officer: SVP, Chief Technology Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Scott D Ericksen	officer: VP, Chief Accounting Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Charles Dadswell	officer: Sr VP & General Counsel	5200 ILLUMINA WAY, SAN DIEGO CA 92122
John Edward Frank	officer: Chief Public Affairs Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Phillip G. Febbo	officer: SVP Chief Medical Officer	C/O GENOMIC HEALTH, INC., 301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carissa Rollins	officer: SVP, Chief Information Officer	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Kevin Carl Pegels	officer: Chief of Global Operations	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Jay T Flatley	officer: President & CEO	9885 TOWNE CENTRE DR, SAN DIEGO CA 92121